Free Newsletter
Toprol OK's a boon for Watson amid shortage
Watson Pharmaceuticals could reap big benefits from the approval of its version of the blood pressure med Toprol XL, because two rival generic drugs were suspended because of manufacturing problems. "We get these opportunities every once in a while and this is one of those unique opportunities," Watson spokeswoman Patty Eisenhaur told Reuters, referring to the sudden recent disappearance from the U.S. market of the rival Novartis and KV Pharmaceutical generics. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





